# NovoCure Ltd (NVCR) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from NovoCure Ltd's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/NVCR/mda/fy2025/): filed 2026-02-26; accession 0001645113-26-000017 (https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/NVCR/mda/fy2024/): filed 2025-02-27; accession 0001645113-25-000002 (https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm)
- [FY 2023 MD&A](/company/NVCR/mda/fy2023/): filed 2024-02-22; accession 0001645113-24-000006 (https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm)
- [FY 2022 MD&A](/company/NVCR/mda/fy2022/): filed 2023-02-23; accession 0001645113-23-000023 (https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm)
- [FY 2021 MD&A](/company/NVCR/mda/fy2021/): filed 2022-02-24; accession 0001645113-22-000011 (https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm)

Back to /company/NVCR/